1. Bausch Faces $3 Billion in Claims Left From Valeant Stock Suit.
- Author
-
Church, Steven and Davis, Michelle F.
- Subjects
STOCKS (Finance) ,CHIEF financial officers ,ACTIONS & defenses (Law) - Abstract
Keywords: 0947744D; 1070L; BHC@CN; ALLTOP; BUSINESS; CANADA; CONS; CONSS; COS; DRG; HEA; INDUSTRIES; LAW; NORTHAM; TOP; US; WORLD; WWTOP; WWTOPAM EN 0947744D 1070L BHC@CN ALLTOP BUSINESS CANADA CONS CONSS COS DRG HEA INDUSTRIES LAW NORTHAM TOP US WORLD WWTOP WWTOPAM Bausch Health Cos. owes a group of investment funds more than $3 billion for stock losses caused by spurious accounting at its predecessor, Valeant Pharmaceuticals, investors suing the company alleged this week. QX27SYT0G1KW (Bloomberg)--Bausch Health Cos. owes a group of investment funds more than $3 billion for stock losses caused by spurious accounting at its predecessor, Valeant Pharmaceuticals, investors suing the company alleged this week. [Extracted from the article]
- Published
- 2021